中文摘要：

目的构建以壳聚糖（Chitosan，CS）为载体的屋尘螨第一变应原组分DNA疫苗（recombinanthousedustmitegroup1allergenvaccine，pVAXl．Derpl／CS），并观察探讨重组DNA疫苗鼻腔黏膜免疫小鼠后对变应性鼻炎（allergicrhinitis，AR）的预防作用及其作用机制。方法复凝聚法制备pVAXl．Derpl／CS纳米粒，对其性质进行分析与鉴定。40只BALB／c小鼠随机分为5组：空白对照组（A组）、阴性对照组（B组，模型组）、空壳聚糖组（C组）、pVAXl-Derpl组（D组）、pVAXl-Derpl／CS纳米粒组（E组）。B、C、D和E组在第1、8天分别予20斗l的磷酸盐缓冲液（phosphatebufferedsaline，PBS）、CS、pVAXl-Derpl、pVAXl-Derpl／CS纳米粒双侧鼻腔交替滴药1次，第15、22天用1μgDerpl＋4mgAI（OH）3400m进行腹腔注射致敏，第36天用20μ1的DerplPBS溶液（0．1μg／ILl）双侧鼻腔交替滴药进行局部激发7d，1次／日。末次激发后2h内处死，比较各组外周血Derpl特异性IgE（DerplspecificIgE，DerplsIgE）、白细胞介素（interleukin，IL）4、IL-10与r干扰素（interferon r，IFN—Jy）的水平，以及鼻黏膜组织炎性反应情况。结果成功构建pVAXl-Derpl／CS纳米粒，其平均粒径为（205．3±12．8）nm，zeta电位为（30．5±5．6）mV。在鼻黏膜组织，B、C组呈明显的变态反应性炎症，D、E组变态反应性炎症较B、C组明显减轻。外周血清中DerplsIgE含量在D组[（109．6±14．5）ng／m1]和E组[（88．1±8．3）rig／m1]低于B组[（120．0±8．8）ng／m1]，差异有统计学意义（t值分别为3．5、6．9，P值均〈0．01）；IL-4水平在D组[（192．5±10．2）pg／m1]和E组[（165．7±9．7）pg／m1]低于B组[（248．7±10．6）pg／m1]，差异有统计学意义（t值分别为10．0、15．2，P值均〈0．01）；IFN-r水平在D组[（856。3±37．4）pg／m1]和E组[（904．8±37．7）pg／m1]高于B组[（709．0±26．5）pg／m1]，差异有统计学意义（t值分

英文摘要：

Objective To study the preparation of recombinant house dust mite group 1 allergen vaccine （chitosan-pVAX1-Derpl nanoparticles, pVAX1-Derpl/CS ） and to investigate the efficacy and mechanism of intranasally given chitosan-pVAX1-Derpl nanoparticles on mouse model with allergic rhinitis （AR）. Methods The chitosan-pVAX1-Derpl nanoparticles was prepared by complex coacervation, and its nature was identified and analysed. A total of 40 BALB/c rats were randomly divided into 5 groups： the normal group （group A）, the AR model group （group B）, the chitosan （CS） prevention group （group C）, the pVAX1-Derp1 prevention group （group D）, and the pVAX1-Derpl/CS prevention group （group E）.The nasal cavity of rats in the group B, C, D and E were dripped with phosphate buffered saline （20 μ1）, CS（20 ILl）, pVAX1-Der pl （20 μl）, pVAX1-Derpl/CS nanoparticles（20 μl） on the first day and day 8, once daily. Rats in the latter 4 group were sensitized with Der pl and AI（ OH）3 in day 15 and day 22, and challenged with Der pl to establish AR model from day 36 to day 43, while rats in group A were treated with PBS. Then the level of cytokines in serum was assayed by ELISA, inflammatory reactions in nasal mucosa were analyzed by haematoxylin and eosin staining. Results pVAX1-Derpl/CS nanoparticles was successfully constructed, the mean grain size of pVAX1-Derpl/CS was （205.3 ± 12. 8） nm, and the zeta potential was （30. 5 ± 5.6 ） mV. In nasal mucosa tissue, group B and C showed significant allergic inflammation, while group D and E showed lighter allergic inflammation. Compared with the group B, the group D and E could effectively reduced serum IgE level and IL-d level [ group B ： （ 120. 0 ± 8. 8 ） ng/ml, （248. 7 ±10. 6） pg/ml; group D： （ 109. 6 ± 14. 5） ng/ml, （ 192. 5 ± 10. 2） pg/ml; group E： （88.1 ± 8.3） ng/ml, （ 165.7 ±9. 7） pg/ml; IgE：t value were 3.5, 6. 9,all P 〈 O. 01 ; IL-4： t value were 10. O, 15.2, all P 〈 0. 01 ], and incr